Simulations Plus (SLP) to Release Earnings on Thursday

Simulations Plus (NASDAQ:SLP) is anticipated to release its Q2 2026 results before the market opens on Thursday, April 2nd. Analysts expect Simulations Plus to post earnings of $0.27 per share and revenue of $21.6590 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, April 2, 2026 at 5:00 PM ET.

Simulations Plus (NASDAQ:SLP) last posted its earnings results on Thursday, January 8th. The technology company reported $0.13 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.05). The firm had revenue of $18.42 million for the quarter, compared to analyst estimates of $18.05 million. Simulations Plus had a positive return on equity of 14.02% and a negative net margin of 81.66%.During the same period in the prior year, the business posted $0.17 EPS. On average, analysts expect Simulations Plus to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Simulations Plus Stock Performance

Shares of Simulations Plus stock opened at $11.54 on Thursday. The firm has a 50-day moving average of $14.27 and a 200-day moving average of $16.20. The stock has a market cap of $232.50 million, a PE ratio of -3.61 and a beta of 1.17. Simulations Plus has a 52-week low of $11.16 and a 52-week high of $36.45.

Analyst Ratings Changes

Several analysts have weighed in on SLP shares. Wall Street Zen upgraded shares of Simulations Plus from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Citigroup reaffirmed a “market perform” rating on shares of Simulations Plus in a report on Tuesday, January 6th. BTIG Research downgraded shares of Simulations Plus from a “buy” rating to a “neutral” rating in a research report on Thursday, December 18th. TD Cowen reiterated a “hold” rating on shares of Simulations Plus in a research note on Thursday, January 8th. Finally, Zacks Research downgraded Simulations Plus from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 2nd. Three analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Simulations Plus presently has an average rating of “Hold” and an average price target of $25.00.

Institutional Trading of Simulations Plus

Hedge funds have recently added to or reduced their stakes in the stock. First Light Asset Management LLC boosted its holdings in shares of Simulations Plus by 156.4% during the 4th quarter. First Light Asset Management LLC now owns 1,968,917 shares of the technology company’s stock valued at $35,893,000 after acquiring an additional 1,201,157 shares in the last quarter. Marshall Wace LLP increased its holdings in Simulations Plus by 127.5% in the 4th quarter. Marshall Wace LLP now owns 569,783 shares of the technology company’s stock worth $10,387,000 after purchasing an additional 319,301 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Simulations Plus by 278.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 427,865 shares of the technology company’s stock valued at $7,800,000 after purchasing an additional 314,844 shares during the last quarter. Squarepoint Ops LLC raised its position in Simulations Plus by 522.1% in the third quarter. Squarepoint Ops LLC now owns 220,103 shares of the technology company’s stock valued at $3,317,000 after purchasing an additional 184,725 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in shares of Simulations Plus by 25.3% during the second quarter. Ameriprise Financial Inc. now owns 875,447 shares of the technology company’s stock valued at $15,277,000 after purchasing an additional 176,747 shares in the last quarter. Institutional investors and hedge funds own 78.08% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.